Development of a Novel Hepatitis C Protease Inhibitor
نویسندگان
چکیده
منابع مشابه
الگوهای جدید درمانی برای عفونت ویروس هپاتیت C
Hepatitis C virus (HCV) infection has affected approximately 180 million people across the world. In most cases, HCV-infection remains chronic, which expose patients at high risk of cirrhosis and hepatocellular carcinoma. The rates of disease incidence and mortality diminish as a result of successful treatment of HCV infection. Until the recent years, despite the associated toxicities and l...
متن کاملغربالگری بیوانفورماتیکی مهارکننده(های) پروتئاز NS3/4A ویروس هپاتیت سی از دو گیاه دارویی Cornus officinalis و Syzygium aromaticum
Background: The hepatitis C virus (HCV) infection is a major global health problem and one of the common causes of mortality worldwide. Therefore, currently many studies have been focused on introducing novel and effective anti HCV agents especially plant materials. Therefore, the study was aimed to screening novel HCV protease inhibitor(s) from two medicinal plants including Cornus officinalis...
متن کاملفراوانی هپاتیتB ، هپاتیتC و ارتباط آنها با ایجاد مهار کننده فاکتور VIII در مبتلایان هموفیلی استان همدان- 1383
Abstract: Background: Hemophilia is a x-linked deficiency of factor VIII. The aim of the present study was to determine the frequencies of hepatitis B and C infections, markers of inflammation and liver function tests and also to assess the possible association between factor VIII inhibitor and hepatitis B and C infections in hemophiliacs of Hamedan Province of Iran. Materials and methods: Si...
متن کاملThe Discovery and Development of Boceprevir: A Novel, First-generation Inhibitor of the Hepatitis C Virus NS3/4A Serine Protease
An estimated 2-3% of the world's population is infected with hepatitis C virus (HCV), making it a major global health problem. Consequently, over the past 15 years, there has been a concerted effort to understand the pathophysiology of HCV infection and the molecular virology of replication, and to utilize this knowledge for the development of more effective treatments. The virally encoded non-...
متن کاملMutations conferring resistance to a potent hepatitis C virus serine protease inhibitor in vitro.
BILN 2061 is a novel, specific hepatitis C virus (HCV) NS3 serine protease inhibitor discovered by Boehringer Ingelheim that has shown potent activity against HCV replicons in tissue culture and is currently under clinical investigation for the treatment of HCV infection. The poor fidelity of the HCV RNA-dependent RNA polymerase will likely lead to the development of drug-resistant viruses in t...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره شماره
صفحات -
تاریخ انتشار 2009